Alembic Pharmaceuticals receives US FDA EIR for Panelav oncology facility
US FDA inspection for injectable and oral solid formulation unit conducted in October 2024 has been successfully closed
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Establishment Inspection Report (EIR)
US FDA issues EIR for Lupin’s injectable facility in Nagpur
Lupin receives Establishment Inspection Report for injectable unit following US FDA inspection in June 2024
USFDA classifies inspection at Dr Reddy’s API facility as Voluntary Action Indicated
Dr Reddy’s Laboratories receives Establishment Inspection Report for its API manufacturing facility in Bollaram, Hyderabad
Lupin receives US FDA Establishment Inspection Report for Somerset facility
The inspection, conducted in January 2025, confirms compliance standards at Lupin’s New Jersey manufacturing site
Axxelent receives its first US FDA Establishment Inspection Report (EIR)
The US FDA inspected the facility from June 17 to 21, 2024
Aurobindo Pharma gets EIR with VAI status from USFDA for Hyderabad facility
USFDA issues an EIR to the company when an inspection is satisfactorily closed
Strides arm receives EIR for its US facility
Strides Pharma Inc received EIR from the United States Food and Drug Administration (USFDA) for the inspection conducted at its…
Cipla announces closure of USFDA inspection at Patalganga facility
Following the inspection by USFDA in November last year, the company has received the Establishment Inspection Report (EIR),…